[
1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276-283.10.1016/j.jtos.2017.05.00828736335
]Search in Google Scholar
[
2. Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, Boland TS, Buznego C, Gira JP, Goldberg DF, Goldman D, Goyal RK, Jackson MA, Katz J, Kim T, Majmudar PA, Malhotra RP, McDonald MB, Rajpal RK, Raviv T, Rowen S, Shamie N, Solomon JD, Stonecipher K, Tauber S, Trattler W, Walter KA, Waring GO 4th, Weinstock RJ, Wiley WF, Yeu E. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27 Suppl 1:3-47.10.1097/01.icu.0000512373.81749.b7534589028099212
]Search in Google Scholar
[
3. Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, Nelson JD, Nichols KK, Pflugfelder SC, Tanzer JM, Asbell P, Hammitt K, Jacobs DS. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13:118-32.10.1016/j.jtos.2014.12.00125881996
]Search in Google Scholar
[
4. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90-100.10.1001/archophthalmol.2011.364367772422232476
]Search in Google Scholar
[
5. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112:71-81.10.3238/arztebl.2015.0071433558525686388
]Search in Google Scholar
[
6. Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Saf. 2019;42:813-825.10.1007/s40264-019-00810-930868436
]Search in Google Scholar
[
7. Marshall LL, Roach JM. Treatment of Dry Eye Disease. Consult Pharm. 2016;31:96-106.10.4140/TCP.n.2016.9626842687
]Search in Google Scholar
[
8. Villatoro AJ, Fernández V, Claros S, Alcoholado C, Cifuentes M, Merayo-Lloves J, Andrades JA, Becerra J. Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy. Int J Mol Sci. 2017;18(11). pii: E2264.10.3390/ijms18112264571323429143779
]Search in Google Scholar
[
9. Harrell CR, Simovic Markovic B, Fellabaum C, Arsenijevic A, Djonov V, Arsenijevic N, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Eye Diseases. Adv Exp Med Biol. 2018;1089:47-57.10.1007/5584_2018_21929774506
]Search in Google Scholar
[
10. Harrell CR, Fellabaum C, Simovic Markovic B, Arsenijevic A, Volarevic V. Therapeutic potential of “Exosomes derived Multiple Allogeneic Proteins Paracrine Signaling: Exosomes d-MAPPS” is based on the effects of exosomes, immunosuppressive and trophic factors. Ser J of Exp Clin Res. 2018; doi:10.2478/sjecr-2018-0032.10.2478/sjecr-2018-0032
]Search in Google Scholar
[
11. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol. 2004; 32:180-184.10.1111/j.1442-9071.2004.00782.x15068436
]Search in Google Scholar
[
12. Arsenijevic M, Milovanovic M, Jovanovic S, Arsenijevic N, Markovic BS, Gazdic M, Volarevic V. In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells. J Biol Inorg Chem. 2017;22:807-817.10.1007/s00775-017-1459-y28421385
]Search in Google Scholar
[
13. Asiedu K, Kyei S, Mensah SN, Ocansey S, Abu LS, Kyere EA. Ocular surface disease index (OSDI) versus the standard patient evaluation of eye dryness (SPEED): a study of a nonclinical sample. Cornea 2016; 35:175-180.10.1097/ICO.000000000000071226655485
]Search in Google Scholar
[
14. Finis D, Pischel N, König C, Hayajneh J, Borrelli M, Schrader S, Geerling G. Comparison of the OSDI and SPEED questionnaires for the evaluation of dry eye disease in clinical routine. Ophthalmologe. 2014;111:1050-1056.10.1007/s00347-014-3042-z25030896
]Search in Google Scholar
[
15. Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease. Exp Eye Res. 2013;117: 118-25.10.1016/j.exer.2013.08.013385583824012834
]Search in Google Scholar
[
16. Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083-94.10.2147/OPTH.S110557
]Search in Google Scholar
[
17. Dohlman TH, Ding J, Dana R, Chauhan SK. T Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+ Myeloid Cell Maturation and Migration. Invest Ophthalmol Vis Sci. 2017;58:1330-1336.10.1167/iovs.16-20789534162428241321
]Search in Google Scholar
[
18. Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014;40:248-56.10.1097/ICL.0000000000000042423182825390549
]Search in Google Scholar
[
19. Harrell CR, Simovic Markovic B, Fellabaum C, Miloradovic D, Acovic A, Miloradovic D, Arsenijevic N, Volarevic V. Exo-d-MAPPS attenuates production of inflammatory cytokines and promotes generation of immunosuppressive phenotype in peripheral blood mononuclear cells. Ser J of Exp Clin Res. 2019; doi: 10.2478/sjecr-2019-0045.10.2478/sjecr-2019-0045
]Search in Google Scholar
[
20. Chen HW, Chen HY, Wang LT, Wang FH, Fang LW, Lai HY, Chen HH, Lu J, Hung MS, Cheng Y, Chen MY, Liu SJ, Chong P, Lee OK, Hsu SC. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol. 2013;190:5065-77.10.4049/jimmunol.120277523589610
]Search in Google Scholar
[
21. Ratay ML, Glowacki AJ, Balmert SC, Acharya AP, Polat J, Andrews LP, Fedorchak MV, Schuman JS, Vignali DAA, Little SR. Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. J Control Release. 2017;258:208-217.10.1016/j.jconrel.2017.05.007780556228501670
]Search in Google Scholar
[
22. Chauhan SK, El Annan J, Ecoiffier T, Goyal S, Zhang Q, Saban DR, Dana R. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009; 182:1247-52.10.4049/jimmunol.182.3.1247263058619155469
]Search in Google Scholar
[
23. Fu R, Jiang Y, Zhou J, Zhang J. Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice. Mol Med Rep. 2019;19:4011-4018.10.3892/mmr.2019.10068647219430896815
]Search in Google Scholar
[
24. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90:1312-20.10.1097/TP.0b013e3181fed00121042238
]Search in Google Scholar
[
25. Harrell CR, Jankovic MG, Fellabaum C, Volarevic A, Djonov V, Arsenijevic A, Volarevic V. Molecular Mechanisms Responsible for Anti-inflammatory and Immunosuppressive Effects of Mesenchymal Stem Cell-Derived Factors. Adv Exp Med Biol. 2019;1084:187-206.10.1007/5584_2018_30631175638
]Search in Google Scholar
[
26. Volarevic V, Zdravkovic N, Harrell CR, Arsenijevic N, Fellabaum C, Djonov V, Lukic ML, Simovic Markovic B. Galectin-3 Regulates Indoleamine-2,3-dioxygenase- Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. Cells. 2019 Jul 12;8(7). pii: E709.10.3390/cells8070709667820231336879
]Search in Google Scholar
[
27. Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, Chieppa M, Rescigno M. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010;59(5):595-604.10.1136/gut.2009.18510820427394
]Search in Google Scholar